Our website uses cookies to improve your on-site experience. By using the website, cookies are being used as described in our Policy Document
Warning: To log in you will need to enable cookies and reload the page (Policy Document)
My ePortfolio Register   

ECCO 15 - ESMO 34 /
Consultant Breast and Endocrine Surgeon, Western Infirmary, Glasgow, Scotland.

20th - 24th Sep 2009

Please rate this video

Please complete at least one question.

  1. The information in this video was of interest to me Disagree Agree
  2. The information in this video is likely to improve my clinical practice or research Disagree Agree
  3. I would recommend this video to my colleagues Disagree Agree
Thanks for rating
There has been a problem, please refresh and try again.
Published: 30.09.09
Views: 12542

Dr Julie Doughty

Expert interview with Julie Doughty, MD conducted by Prof Gordon McVie

Context / Quiz

Novel hormonal agents in early breast cancer

Target audience:

This educational activity is intended for medical, surgical and radiation oncologists, as well as allied oncology professionals who treat breast cancer.

Statement of need:

In the management of breast cancer there are even more complex issues for debate and decision on management pathways. Women diagnosed with breast cancer face the risk of recurrence even when primary tumours are small and no nodal involvement is present. Recurrence can occur at any time, at any stage of the disease and after any treatment modality, but it is most challenging when it occurs rapidly after primary therapy. Prognosis after local recurrence may be managed by local therapies, but distant metastases as a first event are associated with poor survival prospects. So the planning and individualisation of adjuvant therapy in breast cancer is crucial. New approaches require rigorous testing, and even if effective, costs in terms of money and side effects become important.

Learning objective:

After watching this expert interview participants should be able to:

  • Understand the natural history of early and late breast cancer, the significance of positive receptors, whether oestrogen, progesterone or Her2neu, the relevance to targeted therapy and likely consequences.
  • Know the relative and comparative advantages of tamoxifen and the latest aromatase inhibitors and the different advantages/disadvantages of each.
  • Know the current recently completed trials involving early breast cancer and aromatase inhibitors and ongoing trials which are open to recruitment.


This scientific information may include data/information on investigational uses of compounds/drugs that have not yet been approved by regulatory authorities.

This material was developed for use outside of the US and is to be used in accordance with local laws and regulations.

Supported by an unrestricted educational grant from Novartis

Previous conferences: highlights

Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

ecancer Global Foundation